纳武利尤单抗对比多西他赛治疗经治晚期非小细胞肺癌以中国患者为主的人群:CheckMate 078随机III期临床试验
CheckMate 078是一项随机、开放标签III期临床试验,纳入中国、俄罗斯和新加坡的经治晚期非小细胞肺癌患者504例,2:1随机接受纳武利尤单抗(3 mg/kg每2周)或多西他赛(75 mg/m2每3周)。纳武利尤单抗组中位总生存期12.0个月(95%CI 10.4-14.0)显著优于多西他赛组9.6个月(95%CI 7.6-11.2),HR 0.68(97.7%CI 0.52-0.90),p=0.0006;客观缓解率17% vs 4%,≥3级治疗相关不良事件发生率10% vs 48%。
要点
- 纳武利尤单抗组中位OS 12.0个月(95%CI 10.4-14.0)vs 多西他赛组9.6个月(95%CI 7.6-11.2),HR 0.68(97.7%CI 0.52-0.90),p=0.0006。
- 客观缓解率纳武利尤单抗组17% vs 多西他赛组4%;中位缓解持续时间纳武利尤单抗组未达到 vs 多西他赛组5.3个月。
- ≥3级治疗相关不良事件发生率纳武利尤单抗组10% vs 多西他赛组48%。
核心结论
- 在以中国患者为主的经治晚期非小细胞肺癌人群中,纳武利尤单抗对比多西他赛改善总生存期,结果与全球CheckMate 017和057研究一致。
研究设计与样本
- CheckMate 078为随机、开放标签、III期临床试验,纳入中国、俄罗斯和新加坡的鳞状或非鳞状非小细胞肺癌患者,含EGFR/ALK改变者排除。
- 患者共504例,2:1随机接受纳武利尤单抗(3 mg/kg每2周)或多西他赛(75 mg/m2每3周),按体能状态、肿瘤组织学和肿瘤程序性死亡配体1表达分层。
- 主要终点为总生存期,次要终点包括客观缓解率、无进展生存期和安全性。
主要发现
- 纳武利尤单抗组(n=338)对比多西他赛组(n=166)中位总生存期:12.0个月(95%CI 10.4-14.0)vs 9.6个月(95%CI 7.6-11.2),HR 0.68(97.7%CI 0.52-0.90),p=0.0006。
- 客观缓解率纳武利尤单抗组17% vs 多西他赛组4%;中位缓解持续时间纳武利尤单抗组未达到 vs 多西他赛组5.3个月。
- 最短随访时间为8.8个月。
- ≥3级治疗相关不良事件发生率纳武利尤单抗组10% vs 多西他赛组48%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Data on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab in a predominantly Chinese patient population with previously treated NSCLC. METHODS: CheckMate 078 was a randomized, open-label, phase III clinical trial in patients from China, Russia, and Singapore with squamous or nonsquamous NSCLC that had progressed during/after platinum-based doublet chemotherapy (ClinicalTrials.gov: NCT02613507). Patients with EGFR/ALK alterations were excluded. Patients (N = 504) were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks), stratified by performance status, tumor histology, and tumor programmed death ligand 1 expression. The primary endpoint was overall survival (OS); secondary endpoints included objective response rate, progression-free survival, and safety. RESULTS: OS was significantly improved with nivolumab (n = 338) versus docetaxel (n = 166); median OS (95% confidence interval): 12.0 (10.4-14.0) versus 9.6 (7.6-11.2) months, respectively; hazard ratio (97.7% confidence interval): 0.68 (0.52-0.90); p = 0.0006. Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 months. Minimum follow-up was 8.8 months. The frequency of grade 3 or greater treatment-related adverse events was 10% with nivolumab and 48% with docetaxel. CONCLUSIONS: This is the first phase III study in a predominantly Chinese population reporting results with a programmed death 1 inhibitor. In this population with previously treated advanced NSCLC, nivolumab improved OS versus docetaxel. Results were consistent with global CheckMate 017 and 057 studies.
引用
- Wu YL, Lu S, Cheng Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. J Thorac Oncol. 2019. PMID: 30659987. doi:10.1016/j.jtho.2019.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。